OBJECTIVES:HIV-1 transmitted drug resistance (TDR) in treatment-naïve individuals is a well-described phenomenon. Baseline genotypic resistance testing is considered standard of care in most developed areas of the world. The aim of this analysis was to characterize HIV-1 TDR and the use of resistance testing in START trial participants. METHODS: In the Strategic Timing of AntiRetroviral Treatment (START) trial, baseline genotypic resistance testing results were collected at study entry and analysed centrally to determine the prevalence of TDR in the study population. Resistance was based on a modified 2009 World Health Organization definition to reflect newer resistance mutations. RESULTS: Baseline resistance testing was available in 1946 study participants. Higher rates of testing occurred in Europe (86.7%), the USA (81.3%) and Australia (89.9%) as compared with Asia (22.2%), South America (1.8%) and Africa (0.1%). The overall prevalence of TDR was 10.1%, more commonly to nonnucleoside reverse transcriptase inhibitors (4.5%) and nucleoside reverse transcriptase inhibitors (4%) compared with protease inhibitors (2.8%). The most frequent TDR mutations observed were M41L, D67N/G/E, T215F/Y/I/S/C/D/E/V/N, 219Q/E/N/R, K103N/S, and G190A/S/E in reverse transcriptase, and M46I/L and L90M in protease. By country, the prevalence of TDR was highest in Australia (17.5%), France (16.7%), the USA (12.6%) and Spain (12.6%). No participant characteristics were identified as predictors of the presence of TDR. CONCLUSIONS: START participants enrolled in resource-rich areas of the world were more likely to have baseline resistance testing. In Europe, the USA and Australia, TDR prevalence rates varied by country.
RCT Entities:
OBJECTIVES:HIV-1 transmitted drug resistance (TDR) in treatment-naïve individuals is a well-described phenomenon. Baseline genotypic resistance testing is considered standard of care in most developed areas of the world. The aim of this analysis was to characterize HIV-1 TDR and the use of resistance testing in START trial participants. METHODS: In the Strategic Timing of AntiRetroviral Treatment (START) trial, baseline genotypic resistance testing results were collected at study entry and analysed centrally to determine the prevalence of TDR in the study population. Resistance was based on a modified 2009 World Health Organization definition to reflect newer resistance mutations. RESULTS: Baseline resistance testing was available in 1946 study participants. Higher rates of testing occurred in Europe (86.7%), the USA (81.3%) and Australia (89.9%) as compared with Asia (22.2%), South America (1.8%) and Africa (0.1%). The overall prevalence of TDR was 10.1%, more commonly to nonnucleoside reverse transcriptase inhibitors (4.5%) and nucleoside reverse transcriptase inhibitors (4%) compared with protease inhibitors (2.8%). The most frequent TDR mutations observed were M41L, D67N/G/E, T215F/Y/I/S/C/D/E/V/N, 219Q/E/N/R, K103N/S, and G190A/S/E in reverse transcriptase, and M46I/L and L90M in protease. By country, the prevalence of TDR was highest in Australia (17.5%), France (16.7%), the USA (12.6%) and Spain (12.6%). No participant characteristics were identified as predictors of the presence of TDR. CONCLUSIONS: START participants enrolled in resource-rich areas of the world were more likely to have baseline resistance testing. In Europe, the USA and Australia, TDR prevalence rates varied by country.
Authors: Berta Rodes; Federico García; Carolina Gutierrez; Javier Martinez-Picado; Antonio Aguilera; Maria Saumoy; Alex Vallejo; Pere Domingo; David Dalmau; Maria Angels Ribas; José Luis Blanco; José Pedreira; Maria Jesús Perez-Elias; Manuel Leal; Carmen de Mendoza; Vincent Soriano Journal: J Med Virol Date: 2005-09 Impact factor: 2.327
Authors: Annemarie M J Wensing; David A van de Vijver; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Maire-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A Boucher Journal: J Infect Dis Date: 2005-08-15 Impact factor: 5.226
Authors: Birgitte B Simen; Jan Fredrik Simons; Katherine Huppler Hullsiek; Richard M Novak; Rodger D Macarthur; John D Baxter; Chunli Huang; Christine Lubeski; Gregory S Turenchalk; Michael S Braverman; Brian Desany; Jonathan M Rothberg; Michael Egholm; Michael J Kozal Journal: J Infect Dis Date: 2009-03-01 Impact factor: 5.226
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: C Bradley Hare; John Mellors; Amy Krambrink; Zhaohui Su; Daniel Skiest; David M Margolis; Sheran S Patel; Douglas Barnas; Lisa Frenkel; Robert W Coombs; Francesca Aweeka; Gene D Morse; David W Haas; Valerie Boltz; Sarah Palmer; John Coffin; Diane V Havlir Journal: Clin Infect Dis Date: 2008-08-01 Impact factor: 9.079
Authors: Deenan Pillay; Krishnan Bhaskaran; Suzanne Jurriaans; Maria Prins; Bernard Masquelier; Francois Dabis; Robert Gifford; Claus Nielsen; Court Pedersen; Claudia Balotta; Giovanni Rezza; Marta Ortiz; Carmen de Mendoza; Claudia Kücherer; Gabriele Poggensee; John Gill; Kholoud Porter Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Zoe Fox; Andrew Phillips; Cal Cohen; Jacquie Neuhaus; John Baxter; Sean Emery; Bernard Hirschel; Kathy Huppler Hullsiek; Christoph Stephan; Jens Lundgren Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: Jeffrey A Johnson; Jin-Fen Li; Xierong Wei; Jonathan Lipscomb; David Irlbeck; Charles Craig; Amanda Smith; Diane E Bennett; Michael Monsour; Paul Sandstrom; E Randall Lanier; Walid Heneine Journal: PLoS Med Date: 2008-07-29 Impact factor: 11.069
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Seble G Kassaye; Zehava Grossman; Maya Balamane; Betsy Johnston-White; Chenglong Liu; Princy Kumar; Mary Young; Michael C Sneller; Irini Sereti; Robin Dewar; Catherine Rehm; William Meyer; Robert Shafer; David Katzenstein; Frank Maldarelli Journal: Clin Infect Dis Date: 2016-06-15 Impact factor: 9.079
Authors: Claudia Reinheimer; Anna Wesner; Oliver T Keppler; Hans Wilhelm Doerr; Eva Herrmann; Martin Stürmer; Christoph Stephan Journal: Med Microbiol Immunol Date: 2016-01-08 Impact factor: 3.402
Authors: Saran Vardhanabhuti; David Katzenstein; John Bartlett; Nagalingeswaran Kumarasamy; Carole L Wallis Journal: Open Forum Infect Dis Date: 2016-08-24 Impact factor: 3.835
Authors: Francesca Celletti; Jennifer Cohn; Catherine Connor; Stephen Lee; Anja Giphart; Julio Montaner Journal: J Int AIDS Soc Date: 2016-12-16 Impact factor: 5.396
Authors: J D Baxter; D Dunn; A Tostevin; R L Marvig; M Bennedbaek; A Cozzi-Lepri; S Sharma; M J Kozal; M Gompels; A N Pinto; J Lundgren Journal: HIV Med Date: 2020-12-25 Impact factor: 3.094